Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0R1XT
|
|||
Former ID |
DNC012027
|
|||
Drug Name |
Indol-1-yl-methyl-pyridin-4-yl-amine
|
|||
Synonyms |
CHEMBL152842; Indol-1-yl-methyl-pyridin-4-yl-amine; ZINC3997; SCHEMBL7615812; BDBM50048589
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C14H13N3
|
|||
Canonical SMILES |
CN(C1=CC=NC=C1)N2C=CC3=CC=CC=C32
|
|||
InChI |
1S/C14H13N3/c1-16(13-6-9-15-10-7-13)17-11-8-12-4-2-3-5-14(12)17/h2-11H,1H3
|
|||
InChIKey |
DZLHSFJMKLMKMN-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Adrenergic receptor alpha-2A (ADRA2A) | Target Info | Inhibitor | [1] |
Adrenergic receptor alpha-2B (ADRA2B) | Target Info | Inhibitor | [1] | |
Adrenergic receptor alpha-2C (ADRA2C) | Target Info | Inhibitor | [1] | |
KEGG Pathway | cGMP-PKG signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Panther Pathway | Alpha adrenergic receptor signaling pathway | |||
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
Reactome | Adrenoceptors | |||
Adrenaline signalling through Alpha-2 adrenergic receptor | ||||
Adrenaline,noradrenaline inhibits insulin secretion | ||||
G alpha (i) signalling events | ||||
G alpha (z) signalling events | ||||
Surfactant metabolism | ||||
WikiPathways | Monoamine GPCRs | |||
GPCRs, Class A Rhodopsin-like | ||||
Platelet Aggregation (Plug Formation) | ||||
Integration of energy metabolism | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.